Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Needham & Company Downgrades Pacira Pharmaceuticals (PCRX) to Hold
February 16, 2018 7:20 AM ESTNeedham & Company downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold.
Analyst Serge Belanger commented, "The FDA's briefing documents presaged a difficult AdCom panel review for Exparel's potential label expansion to nerve blocks. Over the 2-day panel, panel members echoed the FDA's concerns... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO Capital
February 16, 2018 6:11 AM ESTBMO Capital lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $32.00 (from $41.00) while maintaining a Market Perform rating.
Analyst Gary Nachman commented, "FDA panel voted against approving the nerve block (NB) indication for Exparel (6 No, 4 Yes). We anticipated a complicated... More
Pacira Pharma (PCRX) to Resume Trading at 4:15 pm ET
February 15, 2018 3:51 PM ESTPacira Pharma (NASDAQ: PCRX) to Resume Trading at 4:15 pm ET
... More